Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

The conversation discusses using finasteride, dutasteride, RU58841, and testosterone to combat hair loss and block DHT, with some users expressing concerns about side effects and vegan options for medication. The discussion also touches on personal experiences with hormone treatments and the desire to maintain a youthful appearance.

The user is allergic to minoxidil and plans to try Redensyl hair serum and derma rolling for hair regrowth. They cannot start finasteride until age 18.

User experienced severe allergic reactions and liver issues after a hair transplant, likely due to antibiotics and medications. Despite trying Minoxidil, the user faced further complications and is now seeking medical advice for potential future transplants.

People are discussing the use of the peptide GHK-Cu for hair and skin, with mixed results. Some users have tried it alongside other treatments like adenosine and melatonin, but have not seen significant improvements, and one user stopped due to cost.

The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.

Concerns about the effectiveness of DHT inhibitors like finasteride and minoxidil due to potential polymorph issues. Experts suggest these concerns are largely unfounded, especially compared to rare cases like ritonavir.

A user shared their experience with hair loss treatments, including finasteride, minoxidil, and RU58841, which improved their hair from a diffuse NW3 to a solid NW2 - 2.5. They noticed significant changes in how people treated them after regrowing their hair, suggesting that attractiveness can greatly impact social interactions and opportunities.

Hair loss treatments like finasteride and minoxidil are becoming more mainstream, with younger men starting early to prevent baldness. Increased sharing of transformations online and proactive approaches by Gen Z are contributing to noticeable changes.

New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

The user experienced significant hair regrowth after 2.5 years of using Minoxidil 5% and hormone replacement therapy (HRT) with Lupron, despite initial scalp irritation. Finasteride was ineffective for them.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

Hair loss treatments discussed include dutasteride and oral minoxidil. The conversation humorously compares male lions' manes to human balding.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The user has been using Pyrilutamide (Pyril) for hair loss for a month alongside finasteride/dutasteride since 2021 but hasn't seen results. They are considering switching to RU58841 due to its many success stories, despite being skeptical about the legitimacy and testing of Pyrilutamide.

The user experienced increased hair shedding after using RU58841, despite initial improvements in scalp condition and appearance. They are considering stopping RU58841 to see if shedding decreases.

The user feels hopeless about hair loss despite using finasteride, dutasteride, minoxidil, and RU58841, and having a hair transplant. They are advised to maintain consistency in treatment, consider increasing dutasteride dosage, and explore topical solutions for better results.

GHK-CU is not considered as effective for hair loss as finasteride, minoxidil, or RU58841, with many users reporting minimal benefits. Some users experienced skin improvements, but its impact on hair is debated and often attributed to concurrent use of other treatments.

User tried oral dut 0.5mg, oral min 5mg, topical RU 80mg, and weekly microneedling at 1.5mm for hair loss. Others commented on the significant improvement and potential for future hair transplant.

A user shared their experience of hair loss progression after one year on dutasteride, expressing disappointment with no improvement and considering other treatments like RU58841. Other users offered mixed responses, some seeing no change, others suggesting the hair loss might have been worse without treatment, and discussing the role of testosterone and DHT in hair loss.

The user shared their successful hair regrowth experience using Dutas, oral and topical minoxidil, vitamin D3, zinc, biotin, a laser cap, natural shampoos, ketoconazole shampoo, retinoic acid lotion, and mesotherapy. They reported no side effects and significant improvement in hair thickness and color over six months.

Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.

Feeding bacteria-free mice with Lactobacillus murinus worsened hair loss, but a regular diet with biotin stopped it. The conversation suggests gut bacteria and diet may influence hair loss, with some skepticism and discussion about other factors like DHT and genetics.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The user mixed RU58841 with Minoxidil for hair loss treatment and experienced reduced hair fall and thicker hair but stopped due to chest pain and muscle twitching. They plan to use a new routine without RU58841 or Finasteride due to side effects, including various topical treatments and peptides.

The user experienced severe side effects from finasteride, including cognitive and sexual issues, despite its effectiveness for hair growth. They are considering switching to RU58841 and seek insights from others who have made a similar change.

Brian Dye's theory links skeletal malocclusion type II to hair loss, suggesting it's a blood flow issue. Treatments mentioned include minoxidil, finasteride, and anti-inflammatory drugs like benaxoprofen.

The user shared progress pictures showing significant improvement in hair loss after using finasteride, RU58841, and undergoing a 3000 graft hair transplant. They plan to get another transplant due to remaining thin areas.

The conversation is about the potential of the RCH-01/Replicel hair loss treatment and its lack of updates since 2013, with the user expressing hope for its success and considering using Minoxidil, finasteride, and dermarolling in the meantime. Other treatments mentioned as promising are Breezula and Tsuji.